NEW YORK, Aug. 21, 2015 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, announces that it is investigating potential securities claims on behalf of investors of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("Northwest" or the "Company") resulting from allegations that Northwest may have issued materially misleading business information to the investing public.
On June 19, 2014, a report published by the website TheStreet.com stated that, "The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct." MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics. On this news, shares of Northwest fell $0.87 per share to $8.04, or more than 10.37%, in intraday trading on June 19, 2014.
On July 7, 2014, a report published by the seekingalpha.com website stated that, "Northwest Bio has been the subject of a massive promotional campaign which has seen the stock price soar." And, "in some cases, authors have used fictitious identities and fake credentials within healthcare or finance. In fact they are simply paid writers." On this news, shares of Northwest fell $0.52 per share to $6.62, or more than 7.28%, in intraday trading on July 7, 2014.
On August 21, 2015, pre-market, news broke that the Company's Phase 3 DCVax-L brain cancer treatment clinical trial in Germany was temporarily halted. A reason is yet to be provided, and Northwest is yet to address the issue publicly. On this news, Northwest shares fell as much as $0.88, or 9.91% during intraday trading on August 21, 2015.
If you purchased shares of Northwest and have suffered a loss from your investment in Northwest common stock and would like to learn more about this investigation, including your ability to potentially recover your losses, please contact us either by email at firstname.lastname@example.org or by telephone at (800) 511-7037 or visit our website at www.tripplevy.com/participate-in-an-action.
Tripp Levy PLLC is a leading national securities and shareholder rights law firm representing both individual and institutional shareholders and, along with its affiliate, have recovered billions of dollars for shareholders. Tripp Levy PLLC is affiliated with Milberg LLP. The National Law Journal has named Milberg one of the "50 Elite Trial Lawyer Firms" and one of the "50 Leading Plaintiff Firms in America."
Attorney advertising. Prior results do not indicate a similar outcome
SOURCE Tripp Levy PLLC